Rapid design and development of CRISPR-Cas13a targeting SARS-CoV-2 spike protein
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
: This study provides a rapid design pipeline for a CRISPR-Cas13a-based antiviral tool against SARS-CoV-2. Moreover, it offers a novel approach for anti-virus study even if the precise structures of viral proteins are indeterminate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445 · cited 4×
“Structural comparison of the SARS-CoV and SARS-CoV-2 RBDs revealed an obvious conformational difference in segment 2 (Figure 3A-B), which resulted from residue variations.”
BackgroundInfluentialCell entry mechanisms of SARS-CoV-2
Shang, J., Wan, Y., Luo, C., Ye, G., Geng, Q., Auerbach, A., & Li, F. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003138117 · Cited by 3,142
RNA targeting with CRISPR–Cas13
Abudayyeh, O. O., Gootenberg, J. S., Essletzbichler, P., Han, S., Joung, J., Belanto, J. J., Verdine, V., Cox, D. B. T., Kellner, M. J., Regev, A., et al. (2017) · Nature · doi:10.1038/nature24049 · Cited by 2,093
Tai, W., He, L., Zhang, X., Pu, J., Voronin, D., Jiang, S., Zhou, Y., & Du, L. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0400-4 · Cited by 1,654 · cited 1×
“The RBD in S is a popular target for the design of neutralizing antibodies, inhibitors, and vaccines [23, 24].”
BackgroundRNA virus interference via CRISPR/Cas13a system in plants
Aman, R., Ali, Z., Butt, H., Mahas, A., Aljedaani, F., Khan, M. Z., Ding, S., & Mahfouz, M. (2018) · Genome Biology · doi:10.1186/s13059-017-1381-1 · Cited by 1,497
Baum, A., Fulton, B. O., Wloga, E., Copin, R., Pascal, K. E., Russo, V., Giordano, S., Lanza, K., Negron, N., Ni, M., et al. (2020) · Science · doi:10.1126/science.abd0831 · Cited by 1,253 · cited 1×
“Given that the S protein plays a key role in the induction of neutralizing antibody and protective immune responses, it is a significant epitope for pharmaceutic design [16, 17].”
BackgroundStrategies for nonviral nanoparticle‐based delivery of CRISPR/Cas9 therapeutics
Chen, F., Alphonse, M., & Liu, Q. (2020) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1609 · Cited by 197 · cited 1×
“Nanoparticle-based vectors show good penetration ability due to their small sizes, but their packaging and localization efficiencies need to be improved [29].”
Background
Cited by
Programmable RNA targeting with the single-protein CRISPR effector Cas7-11
Özcan, A., Krajeski, R., Ioannidi, E., Lee, B., Gardner, A., Makarova, K. S., Koonin, E. V., Abudayyeh, O. O., & Gootenberg, J. S. (2021) · Nature · doi:10.1038/s41586-021-03886-5 · Cited by 263
High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects
Tong, H., Huang, J., Xiao, Q., He, B., Dong, X., Liu, Y., Yang, X., Han, D., Wang, Z., Wang, X., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01419-7 · Cited by 230
Self-citationPoint-of-care COVID-19 diagnostics powered by lateral flow assay
Zhou, Y., Wu, Y., Ding, L., Huang, X., & Xiong, Y. (2021) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2021.116452 · Cited by 180
Kelley, C. P., Haerle, M. C., & Wang, E. T. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111226 · Cited by 61
The double life of CRISPR–Cas13
Bot, J. F., van der Oost, J., & Geijsen, N. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2022.102789 · Cited by 50
Metadata
- Authors
- Wang, L., Zhou, J., Wang, Q., Wang, Y., & Kang, C.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2021
- Volume
- 11
- Issue
- 2
- Pages
- 649-664
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W3097061066
- Cited by
- 64
- References
- 7
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rapid design and development of CRISPR-Cas13a targeting SARS-CoV-2 spike protein. https://app.cochat.ai/papers/10.7150/thno.51479
- The paper
- Wang, L., Zhou, J., Wang, Q., Wang, Y., & Kang, C. (2021). Rapid design and development of CRISPR-Cas13a targeting SARS-CoV-2 spike protein. Theranostics. https://doi.org/10.7150/thno.51479
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.